P I Industries Ltd Q2 FY2023 Concall Summary

Key Takeaways

• Strong quarter, conservative guide kept: Revenue grew 31% YoY on broad-based agchem demand, yet full-year guidance stays at 20%+ as management waits out Rabi season and export schedule uncertainty.
• Order book hits \$1.8 bn: The jump reflects repeat commitments and scale-up of existing products, not a sudden non-agchem breakthrough; management treats it as a comfort signal, not a delivery schedule.
• Margins are improving, but slowly: EBITDA rose 49% on operating leverage and mix, and management sees room for a few hundred bps improvement over last year, though it insists on staying conservative.
• Non-agchem is still a seed, not a harvest: One molecule commercialized, pharma intermediates 2–3 years out, and niche non-agchem positioned as a third engine, but none of it is material to revenue or the order book yet.
• What to watch next quarter: Whether the Rabi season delivers the promised domestic strength, how many of the 3–4 agchem molecules slated for H2 actually commercialize, and any inorganic pharma move.

Revenue Growth: What Drove the Quarter

• Agchem exports led: 29% export growth came from roughly 25% volume and 4% price/currency benefit, driven by existing molecules scaling up and strong Kharif-season demand.
• Domestic business accelerated: 36% growth, with volume contributing ~31% and price ~5%, supported by new brand launches across horticulture, cotton, soybeans and wheat, broadening a portfolio once skewed to rice and cotton.
• Not a China-plus or Europe-plus story: Management explicitly attributed the bigger chunk of growth to long-term technology strength, competitiveness and customer relationships, not temporary supply-chain shifts, though it acknowledged receiving opportunities from Europe.
• Freshness index at 16–18%: Products commercialized in the last three years contribute that share of CSM exports annually; management declined to break out the H1 contribution specifically.

Rajnish Sarna: "the bigger chunk of this growth is coming mainly on account of these factors and not so much so because of this temporary phenomenon of China plus or Europe plus."

Order Book: Size, Composition & What It Means

• Order book reached ~\$1.8 bn: The increase is driven by repeat orders, scale-up of existing products and products launched in the last few years; non-agchem products are at a very initial stage of commercialization and not significant in the book.
• Management frames it as a comfort metric, not a delivery schedule: The order book reflects customer commitments and risk management, not a precise quarter-by-quarter revenue map.
• Asset turns improved: Capacity built in the last couple of years now provides headroom, and management highlighted that higher turns are the payoff from an earlier investment cycle.

Mayank Singhal: "I think it was interesting 2 years ago, people are seen putting a lot of Capex. So, you want to look at what, right. So, this is all looked at what comes in and how that has to be played out. And we were sitting with lower assets turns today we're seeing high turns."

Margins: Expansion with a Conservative Stance

• EBITDA grew 49%, outpacing revenue: Operating leverage from 30% top-line growth while holding fixed costs tight, plus a favourable product mix, drove the expansion even in an inflationary input-cost environment.
• Gross margin inched up 18 bps to 45%: Cost pass-through via price increases in both exports and domestic markets helped, alongside mix effects.
• Guidance is for a few hundred bps improvement over last year: When pressed that FY22 EBITDA margin was ~22% and H1 FY23 already showed ~24%, management confirmed the improvement could be only ~100 bps and insisted on conservatism given volatility and climatical challenges.
• Raw material sensitivity flagged: If raw material prices were to drop 20%, that scenario should mathematically improve EBITDA margin, though no timeline was attached.

Mayank Singhal: "Yes. If you look at where the world is today and the way, we look outlook. We want to be conservative. Yes, there is huge amount of volatility and climatical impact and challenges. And given that, we would still like to stick to our guidance."

Domestic Business: Portfolio Reshaping Underway

• New products are broadening the crop mix: Five products launched so far this fiscal (two in horticulture, one each in cotton and soybeans, plus scaled-up wheat services), with two more planned in Q3, moving the portfolio beyond its historical rice-and-cotton concentration.
• A differentiated trajectory expected over 4–5 years: Management believes the domestic business is at the start of a multi-year shift as recently launched products scale, though it declined to disclose segment-level margins.
• Rabi outlook is promising: Strong monsoon, healthy reservoir levels and higher price realization underpin expectations for continued domestic strength.

Non-Agchem & Pharma: The Third Engine, Still Idling

• One non-agchem molecule commercialized this year: It is at a very early stage and not yet a meaningful contributor to revenue or the order book.
• Pharma intermediates are a 2–3 year story: Organic scale-up from R&D and pilot scale takes time due to pharma approval cycles; inorganic moves could complement or accelerate this, and management continues to evaluate targets domestically and internationally.
• Niche non-agchem applications being seeded: PI is focusing on complex chemistry technologies in value-accretive areas to build market credibility as a third growth engine, but details on platforms or applications were withheld for competitive reasons.
• H2 commercialization pipeline: 3–4 agchem molecules and 1 non-agchem molecule are slated for commercialization in the second half.

Capex, Capacity & Supply-Chain Positioning

• Capex guidance raised to ₹700 crore from ₹650 crore: Management said it has no constraint on investing further and ramping capacity as needed, given current utilization and growth visibility.
• Four of eleven MPP plants are effectively dedicated: Running single products, which signals strong customer commitment and long-duration contracts on those assets.
• Close-to-home supply chains seen as a structural shift: Management framed this as a strategic change for global companies, not a temporary pandemic response, and positioned PI as a beneficiary of that reconfiguration.

Mayank Singhal: "The world is a highly volatile place. And I think somebody asked earlier, is Europe moving here. I don't think that is happening. I would say, okay, China could be an opportunity. But close home supply chains are becoming the strategy for companies."

Guidance & Commitments

Key Metrics